Assessment of the cost effectiveness of non-selective non-steroidal anti-inflammatory drugs (NSAIDs) compared to opioids and selective NSAIDs in the treatment of >65 years osteoarthritis patients: a systematic review

Abstract

The non-selective NSAID naproxen with/without PPI is the most cost-effective option to treat > 65 years OA patients with low risk of gastrointestinal adverse reactions compared to the selective NSAID celecoxib and tramadol whereas the selective NSAID celecoxib with/without PPI is more cost-effective than the non-selective NSAIDs for patients with high risk of gastrointestinal adverse reactions